Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Malaria
NITAG documentation
Scientific publications
2021
Clear all
Type of publications
NITAG documentation
(164)
SAGE documentation
(4)
Scientific publications
(1)
Systematic reviews (SYSVAC)
(227)
Topics
Agenda & Minutes
(2)
Background paper
(27)
Recommendation
(135)
Available to download in languages
English (EN)
(113)
French (FR)
(36)
Spanish (ES)
(12)
German (DE)
(7)
Swedish (SV)
(1)
Regions
Africa
(17)
Americas
(61)
Europe
(74)
South-East Asia
(2)
Western Pacific
(11)
Countries
Diseases
COVID-19
(164)
Malaria
(1)
Ebola
(1)
Hepatitis B
(1)
Herpes zoster
(1)
Influenza
(5)
Pneumococcal disease
(1)
Poliomyelitis
(2)
Rotavirus
(3)
Varicella
(1)
Vaccine topics
Target population
Adults
(3)
Children
(3)
Older adults
(1)
Pregnant women
(4)
Risk group
(2)
Publication date
2021
(165)
2024
(2)
2023
(22)
2022
(81)
2020
(83)
2019
(1)
2017
(3)
2016
(4)
2015
(1)
2010
(1)
165 results found
2021
∙
Haut Conseil de la santé publique
HAS statement relating to the possibility of carrying out a vaccination schedule with two mRNA vaccines of different specialties in exceptional situations - 29 April, 2021
2021
∙
Haute Autorité de Santé
HAS vaccination strategy against Covid-19 - Place of the COMIRNATY® mRNA vaccine in 12-15 year olds - 03 June, 2021
2021
∙
Kathleen Dooling, ACIP
Implementation considerations for COVID-19 Vaccines
2021
∙
UNITAG
Interim Advisory on the introduction of COVID-19 vaccine booster doses in Uganda
2021
∙
NACI
Interim guidance on booster COVID-19 vaccine doses in Canada
2021
∙
ACIP
Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years
2021
∙
ACIP
Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines
2021
Interim Recommendations on the Use of COVID-19 Vaccines in Nigeria
2021
∙
Sara Oliver, ACIP
Janssen COVID-19 Vaccine - ACIP conclusion
2021
∙
JCVI
JCVI advice on the UK vaccine response to the Omicron variant
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register